The Therapeutic Potential of Candoxatril, a Neutral Endopeptidase Inhibitor, in Humans

What is it about?

Candoxatril was the first neutral endopeptidase inhibitor. NEP inhibitors were developed to inhibit the breakdown of the natriuretic peptides, increasing circulating levels in the blood and hence reduce vascular congestion and vasoconstriction. Thos review, evaluates the use of candoxatril in the treatment of heart failure and hypertension.

Featured Image

Why is it important?

Review gives an overview of the potential therapeutic benefit of neutral endopeptidase inhibition in which there has been renewed interest with neprilysin inhibition.